计算溶液所需的质量、体积或浓度。
This is a demo store. No orders will be fulfilled.
| 货号 (SKU) | 包装规格 | 是否现货 | 价格 | 数量 |
|---|---|---|---|---|
| P127550-10mg |
10mg |
现货 ![]() |
| |
| P127550-50mg |
50mg |
现货 ![]() |
| |
| P127550-250mg |
250mg |
期货 ![]() |
|
| 英文别名 | 4340891KFS | BDBM50322535 | Dithioglycerol (VAN) | 3-[2-(imidazo[1,2-b]pyridazin-3-yl)ethynyl]-4-methyl-n-{4-[(4-methylpiperazin-1-yl)methyl]-3-(trifluoromethyl)phenyl}benzamide | 3-(2-(IMIDAZO(1,2-B)PYRIDAZIN-3-YL)ETHYNYL)-4-METHYL-N-(4-((4-METHYLPIPERAZ |
|---|---|
| 规格或纯度 | Moligand™, ≥99% |
| 英文名称 | Ponatinib (AP24534) |
| 生化机理 | 强大的多激酶和pan-Bcr-Abl抑制剂。对表达天然Bcr-Abl或Bcr-AblT3151的细胞系显示有效活性(IC50值分别为0.37和2.0 nM);也以纳摩尔浓度抑制其他Abl激酶结构域突变体。表现出对PDGFRα,c-Src和c-Kit的抑制活性(IC50值分别为1.1、5.4和12.5 nM);有效抑制FGFR和VEGFR家族激酶。口服有效。鉴定为靶向与SARS-CoV-2相互作用的人类宿主蛋白。 |
| 储存温度 | -20°C储存 |
| 运输条件 | 超低温冰袋运输 |
| 作用类型 | 抑制剂 |
| 作用机制 | ABL 原癌基因 1 抑制剂;非受体酪氨酸激酶;细胞周期蛋白依赖性激酶 19 抑制剂;细胞周期蛋白依赖性激酶 8 抑制剂;受体相互作用丝氨酸/苏氨酸激酶 1 抑制剂;受体相互作用丝氨酸/苏氨酸激酶 2 抑制剂;受体相互作用丝氨酸/苏氨酸激酶 3 抑制剂;ret 原癌基因抑制剂 |
| 产品介绍 |
Ponatinib (AP24534)是一种新型有效的作用于Abl, PDGFRα, VEGFR2, FGFR1和Src的多靶点抑制剂, IC50分别为0.37 nM, 1.1 nM, 1.5 nM, 2.2 nM和5.4 nM。A Bcr-Abl (Bcr and c-Abl fusion), FGFR, and Flk-1 inhibitor Ponatinib (AP24534) is a novel, potent multi-target inhibitor of Abl, PDGFRα, VEGFR2, FGFR1 and Src with IC50 of 0.37 nM, 1.1 nM, 1.5 nM, 2.2 nM and 5.4 nM, respectively. |
| 纯度 | ≥99% |
| 作用机制 | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | 参考文献 |
|---|
| PubChem SID | 504769864 |
|---|---|
| 分子类型 | 小分子 |
| IIUPAC Name | 3-(2-imidazo[1,2-b]pyridazin-3-ylethynyl)-4-methyl-N-[4-[(4-methylpiperazin-1-yl)methyl]-3-(trifluoromethyl)phenyl]benzamide |
| INCHI | 1S/C29H27F3N6O/c1-20-5-6-22(16-21(20)8-10-25-18-33-27-4-3-11-34-38(25)27)28(39)35-24-9-7-23(26(17-24)29(30,31)32)19-37-14-12-36(2)13-15-37/h3-7,9,11,16-18H,12-15,19H2,1-2H3,(H,35,39) |
| InChi Key | PHXJVRSECIGDHY-UHFFFAOYSA-N |
| Smiles | CC1=C(C=C(C=C1)C(=O)NC2=CC(=C(C=C2)CN3CCN(CC3)C)C(F)(F)F)C#CC4=CN=C5N4N=CC=C5 |
| Isomeric SMILES | CC1=C(C=C(C=C1)C(=O)NC2=CC(=C(C=C2)CN3CCN(CC3)C)C(F)(F)F)C#CC4=CN=C5N4N=CC=C5 |
| 分子量 | 532.57 |
| Reaxy-Rn | 12923700 |
| Reaxys-RN link address | https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN=12923700&ln= |
| 溶解性 | 溶于DMSO, 最高浓度 (mg/mL): 53.26, 最高浓度(mM): 100;溶于ethanol, 最高浓度 (mg/mL): 26.63, 最高浓度(mM): 50 |
|---|---|
| 熔点 | >160°C |
| 分子量 | 532.600 g/mol |
| XLogP3 | 4.100 |
| 氢键供体数Hydrogen Bond Donor Count | 1 |
| 氢键受体数Hydrogen Bond Acceptor Count | 8 |
| 可旋转键计数Rotatable Bond Count | 6 |
| 精确质量Exact Mass | 532.22 Da |
| 单同位素质量Monoisotopic Mass | 532.22 Da |
| 拓扑极表面积Topological Polar Surface Area | 65.800 Ų |
| 重原子数Heavy Atom Count | 39 |
| 形式电荷Formal Charge | 0 |
| 复杂度Complexity | 910.000 |
| 同位素原子数Isotope Atom Count | 0 |
| 定义的原子立体中心计数Defined Atom Stereocenter Count | 0 |
| 未定义的原子立体中心计数Undefined Atom Stereocenter Count | 0 |
| 定义的键立体中心计数Defined Bond Stereocenter Count | 0 |
| 未定义的键立体中心计数Undefined Bond Stereocenter Count | 0 |
| 所有立体化学键的总数The total count of all stereochemical bonds | 0 |
| 共价键合单元计数Covalently-Bonded Unit Count | 1 |
| 象形图 | GHS06 |
|---|---|
| 信号词 | 危险 |
| 危险声明 |
H301: 吞咽会中毒 H311: 皮肤接触有毒 H331: 吸入会中毒 |
| 预防措施声明 |
P261: 避免吸入灰尘/烟雾/气体/雾/蒸汽/喷雾 P264: 处理后要彻底洗手。 P270: 使用本产品时,请勿进食、饮水或吸烟。 P271: 仅在室外或通风良好的地方使用。 P280: 戴防护手套/穿防护服/戴防护眼罩/戴防护面具。 P321: 特殊处理(请参阅此标签上的...)。 P330: 漱口 P302+P352: 如皮肤沾染:用水充分清洗。 P304+P340: 如误吸入:将人转移到空气新鲜处,保持呼吸舒适体位。 P361+P364: 立即脱掉所有沾染的衣服,清洗后方可重新使用。 P405: 密闭存放 P403+P233: 存放在通风良好的地方。保持容器密闭。 P501: 将内容物/容器处理到。。。 P301+P316: 如果吞咽:立即寻求紧急医疗救助。 P316: 立即寻求紧急医疗救助。 |
| 1. Willemsen-Seegers N, Uitdehaag JCM, Prinsen MBW, de Vetter JRF, de Man J, Sawa M, Kawase Y, Buijsman RC, Zaman GJR. (2017) Compound Selectivity and Target Residence Time of Kinase Inhibitors Studied with Surface Plasmon Resonance.. J Mol Biol, 429 (4): (574-586). [PMID:28043854] |
| 2. Najjar M, Suebsuwong C, Ray SS, Thapa RJ, Maki JL, Nogusa S, Shah S, Saleh D, Gough PJ, Bertin J et al.. (2015) Structure guided design of potent and selective ponatinib-based hybrid inhibitors for RIPK1.. Cell Rep, 10 (11): (1850-60). [PMID:25801024] |
| 3. Cortes JE, Kim DW, Pinilla-Ibarz J, le Coutre PD, Paquette R, Chuah C, Nicolini FE, Apperley JF, Khoury HJ, Talpaz M et al.. (2018) Ponatinib efficacy and safety in Philadelphia chromosome-positive leukemia: final 5-year results of the phase 2 PACE trial.. Blood, 132 (4): (393-404). [PMID:29567798] |
| 4. Hui Huang, Yabin Dai, Yuefen Zhang, Yongning Li, Huazhen Ye, Dan Guo, Qiaomei Lu, Xiaohua Cai. (2023) System to screen and purify active ingredients from herbal medicines using hydrogel-modified human umbilical vein endothelial cell membrane chromatography coupled with semi-preparative high-performance liquid chromatography-offline-high-performance liquid chromatography-mass spectrometry. JOURNAL OF SEPARATION SCIENCE, (2201010). [PMID:37192526] [10.1002/jssc.202201010] |
| 5. Michael Edbert Suryanto, Ferry Saputra, Kevin Adi Kurnia, Ross D. Vasquez, Marri Jmelou M. Roldan, Kelvin H.-C. Chen, Jong-Chin Huang, Chung-Der Hsiao. (2022) Using DeepLabCut as a Real-Time and Markerless Tool for Cardiac Physiology Assessment in Zebrafish. Biology-Basel, 11 (8): (1243). [PMID:36009871] [10.3390/biology11081243] |
| 6. Ferry Saputra, Tzu-Ming Tseng, Franelyne P. Casuga, Yu-Heng Lai, Chih-Hsin Hung, Chung-Der Hsiao. (2025) Application of a ImageJ-Based Method to Measure Blood Flow in Adult Zebrafish and Its Applications for Toxicological and Pharmacological Assessments. Biology-Basel, 14 (1): (51). [PMID:39857282] [10.3390/biology14010051] |
| 7. Jianxia Zhang, Yi Wang, Mengying Wang, Peipei Wang, Hao Yan, Dalong Wang, Jiahao Zheng, Bin Li, Chaoyue Chen, Di Cao, Xiaohui Zheng, Xiaokun Li, Kun Wang, Zhiguo Liu. (2025) Discovery of Novel 2,4,5-Trisubstituted Pyrimidine Derivatives as Potent and Selective FGFR Inhibitors against Gatekeeper Mutants for the Treatment of NSCLC. JOURNAL OF MEDICINAL CHEMISTRY, 68 (5): (5907-5925). [PMID:40032550] [10.1021/acs.jmedchem.5c00124] |